Identifying reliable monoclonal antibodies from hundreds or even thousands of antibody-secreting lymphocytes poses huge challenges. Most monoclonal antibodies are not fully characterized after isolation, since most assays used to test the quality of antibodies, like Western blotting and immunohistochemistry, are not amenable to high-throughput screening. Whilst the affinities of antibodies from large antibody libraries can be estimated by ELISA, their specificities remain untested.
Emerge Biotech revolutionizes monoclonal antibody development by interrogating the specificity and affinity of antibodies during high-throughput screening. Only antibodies that fulfil both criteria are taken forward. This technological advance helps to exclude polyspecificity and off-target effects.
We are using our expertise and knowledge in antibody validation to help you achieving your goals.